Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown RIST brain glioblastoma multiforme not applicable detail...
Unknown unknown Axitinib brain glioblastoma multiforme not applicable detail...
CDKN2A loss Milciclib brain glioblastoma multiforme sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01112527 Phase II Dacomitinib PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma Completed
NCT01837862 Phase Ib/II Mebendazole + Vincristine + Carboplatin + Temozolomide Mebendazole + Bevacizumab + Irinotecan A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting
NCT01891747 Phase Ib/II Bevacizumab + Temozolomide A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma Active, not recruiting
NCT01954576 Phase II NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme Recruiting
NCT02052648 Phase Ib/II Temozolomide indoximod Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Active, not recruiting
NCT03522298 Phase II GDC-0084 Safety, Pharmacokinetics and Efficacy of GDC-0084 in Newly-diagnosed Glioblastoma Multiforme Recruiting